Abstract:Objective To assess the safety of infliximab (IFX) treatment in patients with Crohn's disease(CD).Methods From January 2009 to May 2018,at inflammatory bowel disease (IBD) center of Sir Run Run Shaw Hospital,School of Medicine,Zhejiang University,486 CD patients received the treatment of IFX were enrolled and their clinical data were collected.Univariate and multivariate regression of binary logistic were performed for statistical analysis.Results The median follow-up duration was 31.1 months (12.0 months to 40.0 months).The median duration of IFX therapy was 13.0 months (7.0 months to 21.0 months).Among 486 patients,98 (20.16％) patients reported adverse effects,and 12 (2.47％) patients discontinued the therapy because of adverse effects.Acute infusion reaction was the most common adverse effect in CD patients who received IFX treatment accounting for 41.84％ (41/98) of all the adverse effects,and the incidence was 8.44％.Thirty-nine patients had mild and moderate infusion reaction,and all improved after symptomatic treatment (eight patients discontinued IFX therapy because of recurrent infusion reaction).Two patients developed severe infusion reaction as allergic shock,and both relieved after emergency rescue.Four patients developed late-phase allergic reactions.Among 486 patients,39 (8.02％) patients had infections,including infections of Clostridium difficile,cytomegalovirus,herpeszoster virus,Mycobacterium tuberculosis,and other opportunistic pathogens.There was no cases of infection related death.Thirty-six patients continued with IFX treatment after infection controlled.Among 486 patients,14 (2.88％) patients had severe infection,and all the cases improved after anti-infection treatment.Twenty-seven CD patients with hepatitis B virus (HBV) infection received anti-viral treatments,no active HBV infection was observed.Colon adenocarcinoma was found in one patient under colonoscopy at 22 months after discontinuation of IFX therapy.There were six patients with the history of benign tumors,and no evidence of recurrence,progress or malignancy during treatment.In terms of other rare adverse effects in 486 patients,there were eight (1.64％) patients with liver function injury,two (0.41％) patients with anemia,one (0.21％) patient with peripheral neuropathy,and four (0.82％) patients with skin lesion.Prolonged duration of IFX therapy,without combination of immune-suppressors and with increased baseline body mass index (BMI) were the risk factors of acute infusion reactions.Prolonged duration of IFX therapy and with low baseline albumin level were the risk factors of infections.Conclusions IFX is generally safe as the treatment for CD patients,and its adverse effects can be clinically controlled.Screening before therapy and monitoring during therapy may reduce the risks of adverse effects.

Meta Analysis on Association Between Preoperative Infliximab Administration and Morbidity of Postoperative Infectious Complication in Patients with Ulcerative Colitis

Compare Risk Factors Associated with Postoperative Infectious Complication in Crohn’s Disease with and Without Preoperative Infliximab Therapy: a Cohort Study

The predictive factors for postoperative intra-abdominal septic complications after intestinal resection in patients with Crohn's Disease

P652 Compare Risk Factors Associated with Infectious Complication in Crohn’s Disease with and Without Preoperative Infliximab

The Elevated Risk of Recurrent Clostridioides Difficile Infection in Patients with Inflammatory Bowel Disease: a Systematic Review and Meta-analysis

Systematic Review and Meta-Analysis: Association between Preoperative Ustekinumab and Surgical Complications in Crohn's Disease Patients

Analysis of Adverse Effects of Infliximab Treatment in 486 Patients with Crohn′s Disease

An Observational Study of the Effects of Ω-3 Polyunsaturated Fatty Acid-Supplemented Parenteral Nutrition on Postoperative Complications in Patients with Crohn's Disease.

P907 Impact of preoperative use of biologics on 30-day surgical morbidity and mortality in patients with Crohn’s Disease undergoing ileocolectomy: National Surgical Quality Improvement Program database analysis

Safety of Infliximab During Perioperative Period in Crohn Disease Patients

Risk of Tuberculosis During Infliximab Therapy for Inflammatory Bowel Disease, Rheumatoid Arthritis, and Spondyloarthropathy: A Meta-Analysis

Rrisk factors, pathogenic bacteria and drug resistance of postoperative surgical site infection in patients with Crohn's disease

Systematic review and meta analysis of influence of postoperative intestinal immune nutritional support on infectious compl ications and hospital ization time in gastrointestinal cancer patients

Comparative Effectiveness of Oral Antibiotics, Probiotics, Prebiotics, and Synbiotics in the Prevention of Postoperative Infections in Patients Undergoing Colorectal Surgery: A Network Meta‐analysis

Comparative effectiveness of oral antibiotics, probiotics, prebiotics, and synbiotics in the prevention of postoperative infections in patients undergoing colorectal surgery: A network meta-analysis

The Analysis of Clinical Characteristics and Treatment of 234 Patients with Intractable Ulcerative Colitis

Effect of postoperative early ω-3 polyunsaturated fatty acid-based total parenteral nutrition on postoperative complications for patients with Crohn′s disease

Comparison of accelerated and standard infliximab induction regimens in acute severe ulcerative colitis using propensity score analysis: a retrospective multicenter study in China

Additive efficacy and safety of probiotics in the treatment of ulcerative colitis: a systematic review and meta-analysis

Meta‐analysis of oral antibiotics, in combination with preoperative intravenous antibiotics and mechanical bowel preparation the day before surgery, compared with intravenous antibiotics and mechanical bowel preparation alone to reduce surgical‐site infections in elective colorectal surgery

Interventional effects of oral microecological agents on perioperative indicators of colorectal cancer: a meta-analysis